[Effect of electroacupuncture combined with medication on vascular endothelial cells in the compound hypertension and hyperlipemia rat].
OBJECTIVE
To explore the mechanism of electroacupuncture combined with medication for treatment of compound model of hypertension and hyperlipemia (CMHH).


METHODS
CMHH rat model was made by the way of "2K1C" combined with intragastric perfusion of high fat diet, and a normal group and a pseudosurgery group were set up. After modeling for 4 weeks, the successful model rats who had synchronously increase of blood pressure (BP) and blood lipids were randomly divided into a model group, a medication group , an electroacupuncture group and an acupuncture plus medication group. After interference of 4 weeks, changes of BP, total cholesterol (TC) and thiglyceride (TG) and contents of serum vWF, tissue plasminogen activator (t-PA ) and plasminogen activator inhibitor-1 (PAl-1) were observed.


RESULTS
After interference, the levels of BP, TC, TG, vWF, t-PA and PAl-1 significantly changed in all the treatment groups as compared with those in the model group (P < 0.05 or P < 0.01) with most significantly changed in the electroacupuncture plus medication group.


CONCLUSIONS
Both electroacupunctore and electroacupuncture combined with medication can down-regulate levels of BP, TC, TG, and decrease plasma vWF and PAl-1 levels, increase t-PA content, so as to effectively prevent and treat CMHH and possibly induced cerebral diseases.
Yang
Jun
J
Acupuncture Hospital Affiliated to Anhui College of TCM, Hefei 230061, China. yangzyun@yahoo.com.cn
Li
Fei
F
Zhang
Qing-Ping
QP
Wang
Ke-Ming
KM
Hong
Wei
W
Wu
Sheng-Bing
SB
Zhou
Yi-Ping
YP
D000818:Animals; D002784:Cholesterol / Q000097:blood; D015671:Electroacupuncture; D042783:Endothelial Cells / Q000502:physiology*; D005260:Female; D006949:Hyperlipidemias / Q000097:blood / Q000628:therapy*; D006973:Hypertension / Q000097:blood / Q000628:therapy*; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D010959:Tissue Plasminogen Activator / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014841:von Willebrand Factor / Q000032:analysis
D017395:Plasminogen Activator Inhibitor 1; D014280:Triglycerides; D014841:von Willebrand Factor; D002784:Cholesterol; D010959:Tissue Plasminogen Activator